Abstract Aim Cognitive behavioral stress management (CBSM) has been introduced for the postoperative cancer management, but its application in intrahepatic cholangiocarcinoma (ICC) is rare. This current study constructed an offline to online CBSM (OO‐CBSM) program and applying multiple assessing scales, aiming at exploring the benefits of OO‐CBSM regarding anxiety, depression, spiritual well‐being, and quality of life (QoL) in postoperative ICC patients. Methods The study randomly assigned 68 postoperative ICC patients into OO‐CBSM ( N = 34) and normal care (NC) ( N = 34) groups to undergo 10‐week interventions. Hospital anxiety‐and‐depression scale (HADS), Zung's self‐reporting anxiety scale (SAS), and depression scale (SDS), functional‐assessment of chronic‐illness therapy‐spiritual well‐being scale (FACIT‐Sp), European quality‐of‐life‐5 dimensions (EQ‐5D), and quality‐of‐life questionnaire‐core30 (QLQ‐C30) were assessed within 6 months (M). Results HADS‐anxiety scores at M3 ( P = 0.049) and M6 ( P = 0.009), SAS score at M6 ( P = 0.028), HADS‐depression score at M3 ( P = 0.043), and SDS scores at M3 ( P = 0.044) and M6 ( P = 0.028), were lower in the OO‐CBSM group versus the NC group. Meanwhile, FACIT‐Sp scores at M1 ( P = 0.042) and M6 ( P = 0.003) were higher in the OO‐CBSM group over the NC group. Besides, EQ‐5D scores at M3 ( P = 0.067) and M6 ( P = 0.087) disclosed trends to be lower in the OO‐CBSM group versus the NC group, but not statistically significant. QLQ‐C30‐global‐health scores at M3 ( P = 0.049) and M6 ( P = 0.033), and QLQ‐C30‐function score at M6 ( P = 0.046), were higher in OO‐CBSM group over NC group; but QLQ‐C30‐symptom score was not significantly different at any timepoints between them. Conclusion OO‐CBSM attenuates anxiety and depression, and advances spiritual well‐being and QoL in postoperative ICC patients, indicating its potency for the ICC postoperative management.
The T790M mutation in the epidermal growth factor receptor (EGFR) gene is the primary cause of resistance to EGFR-tyrosine kinase inhibitor (TKI) therapy in non-small cell lung cancer (NSCLC) patients. Previous research demonstrated that certain traditional Chinese medicine (TCM) monomers exhibit anti-tumor effects against various malignancies. This study aims to investigate the potentials of shikonin screened from a TCM monomer library containing 1060 monomers in killing EGFR-T790M drug-resistant NSCLC cells and elucidate the underlying mechanisms. MTT method was used to screen for the TCM monomers with significant killing effects on H1975 cells carrying the EGFR-T790M mutation. The influences of the identified monomer shikonin on cell growth were determined by the colony formation assay. Annexin-V/PI staining and JC-1 staining were applied to detect the effects of shikonin on cell apoptosis. The influences of shikonin on cell membrane integrity were detected by lactate dehydrogenase (LDH) release assay. Reactive oxygen species (ROS) generation was analyzed using DCFH-DA as probe. The mechanisms of shikonin affecting the stability of cyclooxygenase-2 (COX-2) were evaluated by using specific inhibitors for protein degradation pathways. Western blotting was performed to assess the effects of the alteration of COX-2 expression or enzymatic activity on the related signal pathways as well as the apoptotic and pyroptotic markers. Shikonin was identified as a potent cytotoxic compound against EGFR-T790M-mutant NSCLC cells. Shikonin induced cell apoptosis and pyroptosis by triggering the activation of the caspase cascade and cleavage of poly (ADP-ribose) polymerase and gasdermin E by elevating intracellular ROS levels. Further investigations revealed that shikonin induced the degradation of COX-2 via the proteasome pathway, thereby decreasing COX-2 protein level and enzymatic activity and subsequently inhibiting the downstream PDK1/Akt and Erk1/2 signaling pathways through the induction of ROS production. Notably, COX-2 overexpression attenuated shikonin-induced apoptosis and pyroptosis, whereas COX-2 inhibition with celecoxib enhanced the cytotoxic effects of shikonin. Combination treatment with shikonin and COX-2 inhibitor may be a suitable therapeutic strategy for EGFR-T790M-mutant NSCLC treatment.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
'%3e%3cg id='b'%3e%3cpath id='a' stroke='%23000' stroke-width='2' d='M-6-25H6m-12 3H6m-12 3H6'/%3e%3cuse xlink:href='%23a' y='44'/%3e%3c/g%3e%3cpath stroke='%23fff' d='M0 17v10'/%3e%3ccircle r='12' fill='%23cd2e3a'/%3e%3cpath fill='%230047a0' d='M0-12A6 6 0 0 0 0 0a6 6 0 0 1 0 12 12 12 0 0 1 0-24z'/%3e%3c/g%3e%3cg transform='rotate(-123.69)'%3e%3cuse xlink:href='%23b'/%3e%3cpath stroke='%23fff' d='M0-23.5v3M0 17v3.5m0 3v3'/%3e%3c/g%3e%3c/svg%3e)